---
title: "Palvella Therapeutics COO Kathleen Goin disposes of 4,302 common shares worth $642,194.57"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293070502.md"
description: "Palvella Therapeutics COO Kathleen Goin sold 4,302 common shares on July 15, 2026, reducing her direct stake to zero. The sales occurred at prices between USD 147.14 and USD 150.25 per share. On the same day, she exercised stock options for these shares at a lower cost basis of USD 7.14 to USD 9.08 per share."
datetime: "2026-07-17T20:06:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293070502.md)
  - [en](https://longbridge.com/en/news/293070502.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293070502.md)
generator: "portal-rs"
---

# Palvella Therapeutics COO Kathleen Goin disposes of 4,302 common shares worth $642,194.57

-   Palvella Therapeutics COO Kathleen Goin sold 4,302 common shares on July 15, 2026, cutting her direct stake to zero. \* Sales priced at USD 147.14 to USD 150.25 per share, weighted-average across multiple trades. \* She exercised stock options for 4,302 shares the same day at USD 7.14 to USD 9.08 per share. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-084620), on July 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)

## Related News & Research

- [Palvella Therapeutics CEO joins Canaccord Genuity Growth Conference fireside chat](https://longbridge.com/en/news/294958978.md)
- [Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram disposes of common shares worth $2.51 million](https://longbridge.com/en/news/297082004.md)
- [BioXcel Therapeutics amends Oaktree-led credit agreement, extends deadline for refinancing deal to Aug. 28](https://longbridge.com/en/news/296776940.md)
- [Nykode Therapeutics announces availability of Q2 2026 financial results report](https://longbridge.com/en/news/297025454.md)
- [Oruka Therapeutics files Form 3 for Chief Commercial Officer Larry Todd Edwards](https://longbridge.com/en/news/297018788.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**